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Gas-phase ion mobility studies of mixtures containing polyethylene glycols (PEG) and an
active pharmaceutical ingredient (API), lamivudine, have been carried out using electrospray
ionization-ion mobility spectrometry-quadrupole-time-of-flight mass spectrometry (ESI-IMS-
Q-TOF). In addition to protonated and cationized PEG oligomers, a series of high molecular
weight ions were observed and identified as noncovalent complexes formed between
lamivudine and PEG oligomers. The noncovalent complex ions were dissociated using
collision induced dissociation (CID) after separation in the ion mobility drift tube to recover
the protonated lamivudine free from interfering matrix ions and with a drift time associated
with the precursor complex. The potential of PEG excipients to act as “shift reagents,” which
enhance selectivity by moving the mass/mobility locus to an area of the spectrum away from
interferences, is demonstrated for the analysis of lamivudine in a Combivir formulation
containing PEG and lamivudine. (J Am Soc Mass Spectrom 2009, 20, 1–9) © 2009 Published
by Elsevier Inc. on behalf of American Society for Mass SpectrometryIon mobility spectrometry (IMS) [1] is a gas-phaseelectrophoretic technique that provides rapid sepa-rations of gas-phase ions on the milliseconds time-
scale. The theory and applications of IMS have been
presented in a number of reviews [2–5]. Gas-phase ions
introduced into the IMS spectrometer are accelerated
through a drift tube, under the influence of a weak electric
field gradient and in the presence of a neutral buffer gas
(typically nitrogen, helium, or air), resulting in the sepa-
ration of ions on the basis of differing mobilities. Ion
mobility, (K (cm2 V1 s1), can be determined from the
time taken for an ion to traverse the drift tube,
K
Vd
E

l2
tdv
(1)
where E (V cm1) is the electric field experienced by the
ion, v (V) is the total applied voltage used to create the
electric field gradient in the drift cell, Vd (cm s
1) is the
average drift velocity of the ion, td(s) is the ion drift
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doi:10.1016/j.jasms.2008.10.002time, and l (cm) is the length of the drift tube. The
mobility of a gas-phase ion is related to its collision
cross section (i.e., size and shape) [6],
K 3ze16N 2kBT
1⁄2 1
D
 (2)
where z is the numerical charge, e is the charge on the ion,
N is the number density of the buffer gas,  is the reduced
mass of the ion and buffer gas, kB is the Boltzmann
constant, T is the temperature, and D is the collision
cross-section.
IMS has been reported for the analysis of active phar-
maceutical ingredients [7–10], veterinary drugs [11], pes-
ticides [12], and narcotics [13–16], using atmospheric or
low-pressure [10 Torr (1333 Pa)] drift tubes. Hyphen-
ated instruments combining low field ion mobility sepa-
rations with MS analyzers (IM-MS) [17] have been used to
identify pharmaceuticals [18–20] and narcotics [21–23].
Desorption electrospray-IM-MS has been reported for the
direct analysis of active pharmaceutical ingredients in
pharmaceutical formulations containing PEG [18], dem-
onstrating the benefits offered by ion mobility separations
for pharmaceutical formulation analyses.
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2 HOWDLE ET AL. J Am Soc Mass Spectrom 2009, 20, 1–9Currently, IMS separations offer low full width at
half height (FWHH) resolutions with typical values
ranging from 10 to 40, limiting the applications of this
technique for the analysis of ions with the same charge
and similar collision cross sections. Increasing the elec-
tric field strength results in relatively higher resolving
power (200) [24]. However, a consequence of high
electric field strength is that the drift gas pressure must
be increased proportionally to maintain a low E/N ratio
(2  1017 V cm2), required for field-independent
mobilities, which may result in lower ion transmission.
The temperature of the drift tube system may also be
decreased to improve resolution, although this favors
cluster formation, making the identification of un-
known samples difficult [25]. The use of drift gasses
other than nitrogen, helium, and air has also been used
to enhance IMS separations [26, 27]. Hill and Asbury
demonstrated that the selectivity of an IMS separation
may be altered by employing drift gasses of different
polarizability [28].
An alternative approach to enhancing selectivity
without altering the instrumental configurations is to
use a shift reagent. A shift reagent is defined as a
species that reacts or complexes with an analyte to form
a gas-phase ion of lower mobility, which increases
(shifts) drift time and enhances separation. Shift re-
agents were first proposed by Creaser et al., on the basis
of studies of the complexation of protonated amines
with crown ethers, using a tandem quadrupole ion
trap/ion mobility spectrometer [29, 30]. These studies
demonstrated enhanced ion mobility separations for the
complexes compared to the free protonated amines.
Reports of IMS studies of noncovalent complexes incor-
porating polyethers have included the analysis of
amino acids [31], amines [29, 30, 32], and peptides [33,
34] with crown ether and linear polyether reagents. IMS
separations of carbohydrates complexed to metal cat-
ions demonstrated the tunable selectivity enhancements
possible by altering the metal salt [35, 36], and recently
functionalized lanthanides have also been applied as
shift reagents to provide selective IMS separations [37].
PEG oligomers are widely used in pharmaceutical
formulations as dosing vehicles, and the collisional
cross sections of sodiated PEG oligomers have been
measured using matrix assisted laser desorption ioniza-
tion (MALDI) [38] over the temperature range 80–600 K
[39–41]. This work was extended to the lithium and
caesium cationized adducts with PEG and a synthetic
derivative [42]. High-field asymmetric waveform ion
mobility spectrometry (FAIMS) [43, 44] and differential
mobility spectrometry (DMS) [45] have also been used
to characterize mixtures of PEG oligomers.
In this paper, we describe an IM-MS study of the
gas-phase, noncovalent complexes of lamivudine, an
active pharmaceutical ingredient, with PEG oligomers,
and discuss the potential of PEGs as shift reagents to
simplify and improve the selectivity for IM-MS analyses
of formulated pharmaceutical ingredients.Experimental
Materials
HPLC grade methanol and analytical reagent (AR)
grade glacial acetic acid were purchased from Fisher
Scientific (Loughborough, UK). Mass spectroscopy
grade (Puriss, p.a.) formic acid and polyethylene glycol
(average molecular weight 400) were purchased from
Sigma-Aldrich (Gillingham, UK). Distilled and deion-
ized water was obtained in-house using a Triple Red
water purification system (Triple Red, Long Crendon,
UK). Lamivudine and Combivir tablets were obtained
from GlaxoSmithKline (Stevenage, UK).
Sample Preparation
Solutions of 49.5/49.5/1 (vol/vol/vol) methanol/water/
formic acid were used in all experiments. Stock solu-
tions of lamivudine (1 mg mL1) were prepared in
methanol and solutions of polyethylene glycol (2 mg
mL1) were prepared in distilled and deionized water.
A stock solution of Combivir was prepared by grinding
a Combivir tablet and dissolving in 100 mL of 49.5/
49.5/1 (vol/vol/vol) methanol/water/formic acid. Ali-
quots of the Combivir stock solution were centrifuged
(Eppendorf, Hamburg, Germany) at 13,200 rpm for 3.5
min to ensure that insoluble matter was not transferred
to the mass spectrometer.
Ion Mobility-Mass Spectrometry Analysis
IM-MS experiments on lamivudine and PEG mixtures
were carried out using a prototype low-pressure ion
mobility-quadrupole-time-of-flight mass spectrometer
(IMS-Q-TOF) based upon a Q-TOF Ultima spectrometer
(Waters, Manchester, UK), which has been described in
detail elsewhere [18]. Sample solutions were delivered
from a gastight glass syringe (500 L; SGE, Sydney,
Australia) to the ESI probe by an integrated syringe
pump (5 L min1). Electrosprayed ion populations
were trapped radially using an RF only trap and
periodically gated into the mobility device [15 ms
repetition period, 200 s pulse width, concurrent flow
of nitrogen gas at2 mbar (200 Pa)]. A voltage gradient
(13.16 V cm1) was applied to the linear ion mobility
drift tube (15.2 cm long). The instrument was operated
in positive ion mode with the ESI capillary set to 3.5 kV.
The nitrogen desolvation gas was set to 500 L h1, the
source temperature to 120 °C, the desolvation temper-
ature to 180 °C, and the cone voltage to 35 V. The
quadrupole mass filter was operated in wide-band-pass
mode (m/z 50 to 1300) and the RF hexapole collision cell
was operated without collision gas (10 V collision cell
energy) to transmit ions into the orthogonal acceleration
TOF region. Single ion mobility spectra were acquired
by measuring 200 sequential TOF scans, where each
TOF scan spaced 65 s apart corresponds to a “bin
number”, over a period of 15 ms from the point of ion
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lated for a 5 s scan time and processed automatically by
combining the mass spectra for all ion mobility separa-
tions. Acquired data were presented as a plot of time
(TOF bin number) against ion intensity (total ion mo-
bility response or selected ion mobility response).
For tandem mass spectrometric experiments, CID
was used; the precursor ion exiting the drift cell region
was selected using the quadrupole mass filter and
accelerated through the collision cell [0.5 mbar (50 Pa)
argon, corresponding cell pressure of 0.7 Pa, 20–50 V
collision energy]. Product ion data were obtained by
combining one hundred 5 s accumulated scans using
Driftscope software (Waters, Manchester, UK).
The analysis of Combivir tablets was carried out
using a Synapt IM-MS spectrometer [46] (Waters,
Manchester, UK) operated in positive ion mode with
the ESI capillary set to 3.0 kV. The nitrogen desolvation
gas was set to 800 L h1, the source temperature to
100 °C, the desolvation temperature to 150 °C, the cone
voltage to 40 V and the nitrogen cone gas flow to 50 L
h1. The quadrupole mass filter was operated in wide-
band-pass mode (analyzing m/z 100–1000). The nitro-
Figure 1. Mass spectrum of a mixture of lami
without ion mobility separation, (a) expanded re
(b) expanded region around protonated lamivud
459), (c) expanded region around the lamivudi
predicted isotopic pattern of the lamivudine/PEG cogen IMS gas flow was set to 20 mL min1 and the IMS
traveling wave velocity to 300 m s1 with a wave height
of 9.0 V. Single ion mobility spectra were acquired by
measuring 200 sequential TOF pushes (45 s). IM-MS
data were accumulated for a 2 s scan time and pro-
cessed automatically by combining the mass spectra for
all ion mobility separations. Sample solutions were
delivered from a gastight glass syringe (250 L; SGE) to
the ESI probe by an integrated syringe pump (2 L
min1). For tandem mass spectrometric experiments the
precursor ions were selected using the quadrupole
mass filter, before acceleration into the trapping region
(5 mL min1 argon corresponding to a trap pressure of
2.98 102 mbar (3.97 Pa), set to 25 V) where they were
subjected to partial fragmentation before entering the
drift cell. Ions were mobility separated in the drift cell
before undergoing further partial fragmentation in
the transfer region (5 mL min1 argon corresponding
to a trap pressure of 2.98  102 mbar (3.97 Pa), set to
6 V) and detected in the TOF region, providing drift
time measurements and tandem mass spectra for the
precursor ion and fragments created in the trapping
region.
e (10 g mL1) and PEG 400 (1000 g mL1)
round the protonated lamivudine ion (m/z 230),
imer and protonated PEG (n 10) oligomer (m/z
EG complex ion (m/z 864, n  14) and, (d) thevudin
gion a
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ne/Pmplex ion.
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Analysis of Lamivudine/PEG Mixture
Infused solutions of lamivudine, an active pharmaceu-
tical ingredient in formulations of Combivir, used to
treat human immunodeficiency virus (HIV) infection,
PEG 400 and lamivudine/PEG mixtures were analyzed
using ESI-IM-MS, generating mass to charge and mo-
Figure 2. Ion series present in a mixture conta
g mL1); (a) mass-to-charge/intensity plot dis
lamivudine/PEG complex ion series and (b) m
intense series of PEG ions and the lamivudi
lamivudine and the protonated lamivudine after
and (filled star), respectively.bility data for the electrosprayed ions. The mass spec-
trum of a mixture containing lamivudine (10 g mL1)
and PEG 400 (1000 g mL1) with concentrations
selected to reflect those found in formulated pharma-
ceutical products is shown in Figure 1. The spectrum of
the lamivudine/PEG mixture is very complex as a
result of overlapping series of protonated and cation-
ized PEG adduct ions. The m/z ratios of the PEG related
lamivudine (10 g mL1) and PEG 400 (1000
ng the most intense series of PEG ions and the
-charge/ion mobility plot displaying the most
EG complex ion series. The free protonated
lexation with PEG are indicated by (filled circle)ining
playi
ass-to
ne/P
comp
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and ion mobility drift time (td) in Figure 2. In addition
to the protonated PEG ion series, other series with 44
and 22 Th repeating units were observed at higher mass
to charge ratios in the mass spectrum. These series are
assigned as cationized (Na and K) adducts of PEG.
Drift time (td) increases with PEG oligomer chain length
for the protonated and cationized ions, reflecting the
increase in collision cross section with chain length [41].
The ion drift times (td)of the [PEG  H]
, [PEG  K],
and [PEG  Na]oligomers were very similar, 0.065
ms (equivalent to 1 bin), with the exception of n  9
where [PEGH] is separated by 0.13 ms (2 bins) from
[PEG  Na]. The gas-phase ion mobilities of the
[PEG  Na] ions are all greater than, or equal, to the
mobilities of the [PEG  H] complexes. This is consis-
tent with the mobilities of alkali metal/crown ether
(18-crown-6) complexes reported by Bowers et al. [47],
which were observed to decrease in the order of: Li 	
Na 	 K 	 Cs. The proposed explanation [47] for the
order of ion mobilities was that the crown ether forms a
more tightly bound complex with ions of high charge
density, such as lithium, to produce smaller collision
cross sectional areas, whereas ions of greater radius and
lower charge density have lower ion mobilities. The
doubly charged ions, [PEG  K  H]2, have higher
mobilities than the corresponding singly charged ions
because mobility is directly proportional to charge state
(eq 2), and this separation between singly and doubly
charged PEG related ions is apparent in Figure 2. The
separation of analytes by charge state has also been
observed in proteomic studies using IM-MS [48]. Mo-
bility separations based on charge provide reductions in
spectral complexity at a given m/z range and signal to
noise improvements, which have been demonstrated in
human drug metabolism and pharmacokinetic (DMPK)
studies using IM-MS [49].
Electrosprayed solutions of lamivudine (L) in the
absence of PEG show [L  H] (m/z 230) and [L2  H]

(m/z 459) ions (data not shown). However, in mixtures
containing PEG, electrosprayed PEG molecules ionize
efficiently and produce a large number of intense
responses, which may mask the weaker signals from
ions such as active pharmaceutical ingredients and
related impurities, presenting difficulties for mass spec-
tra interpretation [19]. Electrosprayed solutions of the
simulated pharmaceutical formulation (Figure 1) dis-
play a weak response for protonated lamivudine [L 
H] at m/z 230 (Figure 1a), which is barely visible above
the baseline. The signal intensity at m/z 459 is strong,
but corresponds to an overlap of the lamivudine [L2 
H] dimer and a PEG oligomer ion [PEGH] (n 10)
that has the same nominal mass to charge ratio as the
lamivudine dimer ion (Figure 1b).
In addition to the protonated and cationized PEG ion
series, a series with a 44 Th repeating unit was observed
at higher m/z and higher drift time than the protonated
and cationized PEG oligomers (Figure 2) in the electro-
sprayed lamivudine/PEG mixture. These ions wereassigned to a series of noncovalent complexes contain-
ing lamivudine and PEG oligomers of increasing chain
length. For example, the ion at m/z 864 (Figure 1c) is
assigned as a lamivudine/PEG, [L  PEG  H]
complex (n  14; C36H70N3O18S). The theoretical isoto-
pic pattern presented in Figure 1d compares well with
the isotopic pattern observed experimentally in Figure
1c. A range of PEG oligomer chain lengths (n  10–19)
were observed in the [L  PEG  H] series using
IM-MS (Figure 2) with selected ions identified using
tandem mass spectrometry.
Total ion and selected ion mobility responses for the
lamivudine/PEG mixture are displayed in Figure 3.
Selected ion responses for protonated lamivudine (m/z
230; Figure 3b), the lamivudine dimer and protonated
PEG ions at m/z 459; (n  10; Figure 3c), the protonated
PEG ions at m/z 503 (n  11; Figure 3d), and m/z 635
(n  14; Figure 3e), and the PEG/lamivudine complex
ions at m/z 732 (n  11; Figure 3f), and m/z 864 (n  14;
Figure 3g) show the mobility separations achieved. A
general trend of decreasing mobility with increasing
mass (corresponding to an increase in the ion collisional
cross section) is observed. The resolution of IMS sepa-
rations attained using our prototype IMS-Q-TOF spec-
Figure 3. Ion mobility spectrum and selected ion mobility re-
sponses for a mixture containing lamivudine (10 g mL1) and
PEG 400 (1000 g mL1); (a) total ion mobility spectrum, (b)
protonated lamivudine (m/z 230), (c) co-drifting lamivudine dimer
and a protonated PEG ion (m/z 459, n  10), (d) protonated
polyethylene glycol (m/z 503; n  11), (e) protonated polyethylene
glycol (m/z 635; n 14), (f) lamivudine/PEG complex ion (m/z 732;
n  11), and (g) lamivudine/PEG complex ion (m/z 864; n  14).
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(FWHH resolution 10–15), but it is unable to mobility
resolve the protonated PEG oligomer (n  10, m/z 459)
and lamivudine dimer (m/z 459) responses, demon-
strated by the single broad peak in the selected ion
mobility spectrum of m/z 459 (Figure 3c). The broad ion
mobility peak for m/z 230 suggests that the protonated
lamivudine may be only partially separated from an
excipient ion. The lamivudine/PEG complex ions have
lower mobilities (longer drift times) than the protonated
and cationized PEG oligomers because of their larger
collision cross sections, and are fully resolved from the
protonated lamivudine ion. The drift times for [L 
PEG  H] and [PEG  H] converge as the PEG
oligomer size (n) increases (Figure 2) and, as a conse-
quence, the resulting mobility responses are less well
resolved. For example, the separation of the [L PEG
H] and [PEG  H] (m/z 732 and 503, respectively) for
the n  11 oligomer chain length is 0.52 ms (8 bins),
whereas the separation of the [L  PEG  H] and
[PEG  H] (m/z 864 and 635, respectively) for the n 
14 oligomer is 0.39 ms (6 bins). These data demonstrate
that as the length of the PEG chain increases, the
contribution to collisional cross section from the
protonated lamivudine ion decreases. However, even
the highest m/z observed for [L  PEG  H] (m/z
1085, n  19; td 4.36 ms) is still partially mobility-
resolved from the corresponding [PEG  H] (m/z
856, n  19; td 3.97).
Figure 4. Tandem mass spectrum (CID) of lam
from the ESI-IMS-Q-(CID)-TOF analysis of a la
filter set pass only m/z 864 showing a lamivudine
protonated PEG (m/z 635) derived from the precu
(insert) the ion mobility spectrum of the recovere
drift time corresponding to the lamivudine/PEG comThe selected ion mobility spectrum of the
lamivudine/PEG complex ion at m/z 864 (n 14; Figure
3g) shows a large shift in mass (
m/z  634) and
mobility (
td  2.3 ms) compared with the protonated
lamivudine (m/z 230; Figure 3b). The response for
lamivudine is therefore shifted through complexation
with PEG oligomers, which is functioning as a “shift
reagent”, to a mass/mobility locus relatively free from
strong interfering PEG responses [indicated by (filled
star) in Figure 2]. Ions of the [L  PEG  H] series
were preselected by mass-to-charge using the quadru-
pole mass filter before entering the collision cell. Tan-
dem mass spectrometry of the noncovalent complex at
m/z 864 (n  14; Figure 4) was performed using CID to
recover the protonated lamivudine (m/z 230), as well as
a lamivudine fragment (m/z 112), and the protonated
PEG oligomer (n  14; m/z 635). Ion mobility spectra
were acquired whilst tandem mass spectrometry (CID)
experiments were performed. The selected ion mobil-
ity response for the protonated lamivudine therefore
has a drift time (td  3.90 ms; bin number 60; Figure
4 insert) corresponding to the [L  PEG  H] (m/z
864, n  14) precursor complex ion, but with an m/z
corresponding to [L  H] (m/z 230). The position of
the recovered m/z 230 product ion, [L  H], is
indicated by (filled circle) in Figure 2 and is located in
a mobility and m/z area free from interfering PEG
ions.
ne/PEG complex ion (m/z 864, n  14) obtained
dine/PEG mixture with the quadrupole mass
ent (m/z 112), protonated lamivudine (m/z 230),
lamivudine/PEG complex (m/z 864; n 14), and
tonated lamivudine (m/z 230) product ion at theivudi
mivu
fragm
rsor
d proplex (m/z 864, n  14; 3.90 ms).
on in
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Containing lamivudine
The experiments on complexation of lamivudine with
PEG were repeated for a Combivir tablet extract, which
contained lamivudine in the presence of PEG excipi-
ents, using a Waters Synapt spectrometer. Figure 5a
shows the mass spectrum, produced after combining all
200 mobility bins, showing lamivudine/PEG complex
[L  PEG  H] formation (indicated by a series of
stars). Figure 5b shows the normalized selected mobil-
ity responses for lamivudine (m/z 230), PEG (m/z 635,
n  14), and the lamivudine/PEG complex (m/z 864,
n  14) acquired with the quadrupole filter positioned
between the ESI source and the ion mobility drift cell set
to pass only m/z 864. The lamivudine and PEG ions
result from CID of the lamivudine/PEG complex before
mobility separation. It is clear from Figure 5 that the
Figure 5. IM-MS data obtained from an elec
100-fold in 49.5/49.5/1 (vol/vol/vol) methanol/
spectrometer showing (a) the mass spectrum o
acquisitions of the ion mobility separation with [
(b) the selected ion mobility responses for lam
lamivudine/PEG complex (m/z 864, n  14) ov
tandem MS experiment with the pusher pulse se
only m/z 864, followed by partial CID dissociatiprotonated lamivudine, PEG, and lamivudine/PEGcomplex ions are fully mobility-resolved. For example,
enhanced mobility separation is achieved through the
shift in drift time for lamivudine to 3.80 ms (bin number
80) as a result of complexation with PEG (n  14). Any
of the PEG/lamivudine complexes may be chosen to
recover the free protonated lamivudine and to max-
imize sensitivity the highest intensity complex should
be isolated. However, the best selectivity may be
achieved by selecting a higher mass complex such as
the m/z 864 (n  14). Figure 6 shows IM-MS data for the
lamivudine/PEG complex (m/z 688, n  10), in which
the selected ions were subjected to partial fragmentation
both before IM separation, in the trapping region before
the drift cell, and in the transfer region after separation
in the drift cell (i.e., ESI-MS-CID-IMS-CID-MS). Figure
6b shows the tandem mass spectrum produced when
the lamivudine/PEG complex (m/z 688, n  10) was
rayed infusion of a Combivir tablet, diluted
r/formic acid, acquired using a Waters Synapt
ed by combining all 200 bins acquired during
PEG  H] complexes indicated by (filled star),
ine (m/z 230), PEG (m/z 635, n  14), and a
d with normalized intensities, obtained from a
5 s and the quadrupole mass filter set to pass
the trap before mobility separation.trosp
wate
btain
L 
ivud
erlai
t to 4fragmented in the transfer region after mobility separa-
vudin
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with the longer drift time (1.89 ms; bin number 42) of
the PEG/lamivudine complex. Figure 6c shows the
tandem mass spectrum of the lamivudine/PEG com-
plex (m/z 688, n  10) fragmented before entering the
drift cell, where protonated lamivudine released from
the [L  P  H] complex ion passed through the IMS
cell and was fragmented in the transfer region to yield
a characteristic fragment ion at m/z 112 with a drift time
of 0.77 ms (bin number 17). Using the combination of
in-trap CID, IMS drift cell separation, and CID in the
transfer region of the Synapt spectrometer provides
drift time measurements and tandem mass spectra for
the fragments of the precursor and fragment ions. The
data presented in Figure 6 therefore demonstrate the
additional increase in selectivity for the IM-MS analyses
using pre- and post-drift cell fragmentation.
Conclusions
A prototype IMS-Q-TOF spectrometer utilizing an ESI
source has been used to study the gas-phase noncova-
lent complexes of an API, lamivudine, with PEG oli-
gomers. A series of noncovalent complex ions contain-
ing the API and PEG were identified using tandem
mass spectrometry. The protonated basic API has a
Figure 6. ESI-MS-CID-IMS-CID-MS spectrum
obtained from an electrosprayed infusion of
(vol/vol/vol) methanol/water/formic acid, acq
pusher pulse set to 65 s showing (a) the tot
obtained at td 2.78 ms (bin number 42) demonstr
lamivudine/PEG complex ions (m/z 688, n  1
shifted drift time associated with the PEG/lami
1.11 ms (bin number 17) demonstrating pre-drift
complex (m/z 688) to yield protonated lamivudin
with a drift time corresponding to the free lamidecreased mobility when present as a noncovalentcomplex with a linear polyether. The potential of linear
PEGs to act as internal shift reagents to enhance the
separation and selectivity is demonstrated using a phar-
maceutical formulation containing PEG with lamivu-
dine. The free protonated lamivudine was recovered by
tandem mass spectrometry with a drift time associated
with the precursor complex. Recovery of the API from
the API/shift reagent complex, by CID confirms the
identity of the API and offers the potential for qualita-
tive detection. Polyethers have the potential to be used
as shift reagents when they are present in a formulation
or could be added before the IM-MS analysis of an API,
providing a method to enhance selectivity without
modification of the ion mobility-mass spectrometer.
Shift reagents may also be used for analyzing complex
mixtures containing basic APIs, using stand alone IMS
instrumentation. However, to avoid false positive re-
sults a lamivudine/PEG complex containing a single
high molecular weight PEG oligomer or an additional
shift reagent should be selected, to shift the mobility of
the complex to an area free from interferences.
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